Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Succinylcholine for Recovery From Neuromuscular Block
NCT00474253Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2006
- Primary completion
- Aug 2006
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
A Phase 3 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Merck & Co.. Started Feb 2006; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00474253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00474253.